TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration
Stopped early · Phase 2
Conditions studied: Age-Related Macular Degeneration
In brief
VERTACL will investigate whether a triple therapy, Avastin®, half fluence verteporfin photodynamic therapy (PDT), and triamcinolone acetonide-preservative free (TAC- PF), results in improved 12-month vision outcome compared to Avastin® alone in participants with neovascular AMD.
Key facts
- Study ID
- NCT00464347
- Run by
- National Eye Institute (NEI)
- People needed
- 100
- Starts
- 2007-01-01
- Expected to finish
- 2007-09-01
- Last updated by the study team
- 2010-03-24
Who can join
Age: 50 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Retinal Group of Florida — Fort Lauderdale, Florida, United States
- Central Florida Retina- Orlando — Orlando, Florida, United States
- Retina Specialists — Pensacola, Florida, United States
- Elman Retina Group- Baltimore — Baltimore, Maryland, United States
- Associated Retinal Consulants — Grand Rapids, Michigan, United States
- VitroRetinal Surgery — Minneapolis, Minnesota, United States
- Duke University Eye Center — Durham, North Carolina, United States
- Palmetto Retina Center — Columbia, South Carolina, United States
- Southeastern Retina Associates — Knoxville, Tennessee, United States
- Texas Retina Associates-Arlington — Arlington, Texas, United States
- Texas Retina Associates-Dallas — Dallas, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.